INmune Bio Advances Clinical Pipeline, Burns Through Cash Reserves
Event summary
- INmune Bio reported a net loss of $45.9 million for 2025, compared to $42.1 million the prior year.
- The company estimates its cash runway extends to Q1 2027, with approximately $24.8 million in cash and equivalents as of December 31, 2025.
- INmune Bio sold 4.3 million shares in 2025, generating $27.5 million in net proceeds.
- The CORDStrom™ program is on track for UK MAA submission mid-summer, followed by EMA and FDA filings.
- XPro™ has achieved alignment on an adaptive Phase 2b/3 registrational pathway with the FDA.
The big picture
INmune Bio's transition to a late-stage clinical company is predicated on the successful advancement of CORDStrom™ and XPro™. While the company has made progress in de-risking its pipeline, the limited cash runway and the inherent uncertainties of clinical development and regulatory approval present significant challenges. The company's ability to secure additional funding and execute its clinical programs efficiently will be crucial for long-term success.
What we're watching
- Capital Needs
- The company's Q1 2027 cash runway highlights the ongoing need for capital, potentially necessitating further equity or debt financing to support late-stage clinical trials and eventual commercialization.
- Regulatory Risk
- The success of CORDStrom™ hinges on timely regulatory approvals in the UK, EU, and US; any delays or rejections could significantly impact the company's valuation and future prospects.
- Clinical Execution
- The adaptive Phase 2b/3 trial design for XPro™ introduces complexity and risk; the go/no-go decision at the Phase 2b stage will be critical in determining the viability of the program.
Related topics